{"id":16962,"date":"2023-11-27T15:40:25","date_gmt":"2023-11-27T15:40:25","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/blog\/the-inflammation-basis-of-metabolic-disease-understanding-the-silent-culprit\/"},"modified":"2023-11-27T15:40:25","modified_gmt":"2023-11-27T15:40:25","slug":"the-inflammation-basis-of-metabolic-disease-understanding-the-silent-culprit","status":"publish","type":"blog","link":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/the-inflammation-basis-of-metabolic-disease-understanding-the-silent-culprit\/","title":{"rendered":"The Inflammation Basis of Metabolic Disease: Understanding the Silent Culprit"},"content":{"rendered":"

Metabolic diseases<\/a> have become a global health crisis, affecting millions of people worldwide. Conditions like obesity, type 2 diabetes (T2D<\/a>), and renal and cardiovascular diseases are rising, and their impact on individuals and society is substantial1<\/sup>. While genetics, lifestyle, and dietary choices play significant roles in developing metabolic diseases, a growing body of research points to a common underlying factor: inflammation. In this blog, we will explore the inflammation basis of metabolic disorders and understand how chronic low-grade inflammation can silently contribute to their development.<\/p>\n

The Interplay of Inflammation and Metabolic Disease: Unravelling a Complex Connection<\/em><\/h2>\n

Inflammation is a complex, highly regulated biological response that helps the body defend itself against harmful stimuli, pathogens or damage. When the immune system detects a threat, it releases soluble mediators and activates immune cells to eliminate the danger and promote tissue repair. This acute, short-term inflammation is a vital part of the body’s immune response and is necessary for healing and recovery from injuries and infections.<\/p>\n

However, chronic, low-grade inflammation is different; it is a persistent, non-resolving, low-level state of inflammation that can have irreversible detrimental effects over time. Such \u201csterile\u201d inflammation develops without external pathogens and responds to perceived damage due to excess fat and cholesterol, hypertension, stress and ageing2<\/sup>. This type of inflammation is not the typical defence mechanism but an ongoing state of heightened immune activity. Nowadays, chronic low-grade inflammation in metabolic organisms<\/a> and tissues, often referred to as \u00ab\u00a0metabolic inflammation\u00a0\u00bb, \u00ab\u00a0meta-inflammation\u201d or \u201cmetaflammation,\u00a0\u00bb is recognized as a key driver of the development and progression of various metabolic diseases and can be confirmed by increased levels of c-reactive protein (CRP), a general biomarker of systemic inflammation.<\/p>\n

Indeed, specific inflammatory signals linked to T2D<\/a> include adipocyte cytokine production, increased proinflammatory M2 macrophages and the loss of immune-suppressing regulatory T cells. Such changes are believed to be significant contributors to the development and progression of these metabolic conditions. Meta-inflammation can disrupt normal metabolic processes, interfere with regulating blood sugar and lipids, and lead to insulin resistance, a hallmark of T2D.<\/p>\n

Fighting Meta-inflammation: Pharmacological Perspectives<\/em>3<\/sup><\/h2>\n

Pharmacological strategies for addressing meta-inflammation involve using medications to prevent or block chronic low-grade inflammation. While these medications are not a single, standalone solution and should be complemented with lifestyle modifications and anti-obesity\/T2D therapies, they can be valuable components of a comprehensive treatment management plan.<\/p>\n

Here are some potential and current pharmacological strategies for addressing meta-inflammation and metabolic disease:<\/h4>\n